KEAP1 and breast carcinoma: At low concentrations (<25 μM), DMF activates Nrf2 by modifying KEAP1, promoting antioxidant gene expression and cytoprotection, as seen in breast cancer models where it reduces tumor invasion via macrophage modulation.